Recent Progresses in the Treatment of Osteoporosis

Abstract

Osteoporosis (OP) is a chronic bone disease characterized by aberrant microstructure and macrostructure of bone, leading to reduced bone mass and increased risk of fragile fractures. Anti-resorptive drugs, especially, bisphosphonates, are currently the treatment of choice in most developing countries. However, they do have limitations and adverse effects, which, to some extent, helped the development of anabolic drugs such as teriparatide and romosozumab. In patients with high or very high risk for fracture, sequential or combined therapies may be considered with the initial drugs being anabolic agents. Great endeavors have been made to find next generation drugs with maximal efficacy and minimal toxicity, and improved understanding of the role of different signaling pathways and their crosstalk in the pathogenesis of OP may help achieve this goal. Our review focused on recent progress with regards to the drug development by modification of Wnt pathway, while other pathways/molecules were also discussed briefly. In addition, new observations made in recent years in bone biology were summarized and discussed for the treatment of OP.

Clinical Parameters in Osteoporosis Patients Supplemented With PMA-Zeolite at the End of 5-Year Double-Blinded Clinical Trial

“…In line with this, the PMA-zeolite treatment may be an interesting option in designing of a patient-tailored long-term osteoporosis treatment regimen where a balanced homeostasis of bone remodeling process is a desired therapeutic outcome. Therapy compliance to the osteoporosis pharmacological therapy remains a challenge as well, due to side effects ( 18 , 19 ) or small benefits for the patient's quality of life ( 19 , 20 ). In the TOP study, the compliance to PMA-zeolite supplementation was 81% and interesting data was obtained within the quality of life assessment as well.…”

Perspectives of personalized approach to prevention and treatment of anticonvulsant-induced osteoporosis via action on vitamin D exchange and VDR expression

“…For patients who cannot tolerate oral bisphosphonates, treatment with parenteral drugs such as zoledronic acid, or ibandronate sodium may be considered [91]. The mainstay of current treatments is still anti-resorptive drugs, particularly, BPPs, in most developing countries [92]. However, such therapy should be offered only after consideration of potential risks and benefits and should be appropriately individualized.…”

Effect of pulsed electromagnetic field versus pulsed high intensity laser in the treatment of men with osteopenia or osteoporosis: a randomized controlled trial

“…Osteoporosis (OP) is a systemic bone disease characterized by a gradual loss of bone mass and tissue degradation, resulting in impaired bone strength, significant deterioration of bone microarchitecture, and decreased bone mass, caused by bone resorption outpacing bone formation, resulting in increased bone fragility and a high fracture risk. 1,2 Osteopenia is a condition marked by low bone mineral density (BMD) that can lead to OP. Because patients have no early symptoms, most OP cases are detected after a fracture.…”